Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

36.69 -0.39 (-1.05%)
Streaming Delayed Price Updated: 3:06 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Viking Therapeutics, Inc. - Common Stock

News headline image
Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)
Via AB Newswire
News headline image
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
Via AB Newswire
News headline image
Is Viking Therapeutics Ready For Another Surge?
Viking Therapeutics' promising weight loss drug could revolutionize the obesity market and propel the company's stock price to new highs. 
Via MarketBeat
News headline image
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market. 
Via MarketBeat
Viking Therapeutics Inc. (NASDAQ: VKTX) is a Stock Spotlight on 5/23
Via Investor Brand Network
News headline image
Viking Therapeutics: Pharma Stock Soars on Positive Earnings
Viking Therapeutics stock soars on clinical trial results and a solid earnings beat, signaling a potential market shake-up in the biopharmaceutical sector. 
Via MarketBeat
Topics Earnings
News headline image
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat
News headline image
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
Via MarketBeat
News headline image
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
Via MarketBeat
News headline image
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
News headline image
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
Via MarketBeat
News headline image
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
News headline image
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
News headline image
MarketBeat Week in Review – 4/1 - 4/5
Equities lost ground this week as investors consider the effect of fewer rate cuts, rising oil prices, and robust job gains ahead of a new earnings season 
Via MarketBeat
Topics Economy
News headline image
Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher 
Via MarketBeat
News headline image
7 Stocks That Will Drive the Weight Loss Drugs Market
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. 
Via MarketBeat
News headline image
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher 
Via MarketBeat
Viking Therapeutics Inc. (NASDAQ: VKTX) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
News headline image
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
Via MarketBeat
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies. 
Via MarketBeat
News headline image
Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme 
Via MarketBeat
Viking Therapeutics Inc. (NASDAQ: VKTX) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP 
Via MarketBeat
News headline image
Why Did Viking Therapeutics Stock Skyrocket
VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial. 
Via MarketBeat
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.